Depression, Depressive Disorder, Depressive Symptoms
Conditions
Keywords
African American
Brief summary
The goal of this clinical trial is to see if a mobile phone app can deliver depression treatment to African Americans who are depressed. The main question it aims to answer is if this treatment is effective in reducing symptoms of depression. Participants will attend six 90-minute weekly classes via an app on their phone, and will be asked to complete surveys every week. Participants can expect to be in the study for four months.
Detailed description
The Oh Happy Day Class-Digital Connections (OHDC-DC) is designed for African American adults experiencing clinical depression (CD). OHDC originally comprised of 13 treatment modules focused on culturally relevant strategies to increase knowledge of depression and healthy coping behaviors aimed at reducing symptoms of clinical depression and improving health outcomes. The Oh Happy Day Class-Digital Connections (OHDC-DC) comprise of 5 core elements of the OHDC-DC: 1. 90-minute-weekly cognitive behavioral psycho-education classes over a 6-week period. 2. Six classes will be offered and facilitated online in the computerized OHDC-DC. 3. Participants will be encouraged to stay engaged between classes by digitally connecting on the app with the class content. On the app they will receive reminders and messages from staff and participants to stay digitally connected and engaged. 4. Embedded in the classes and content is psychoeducation with an emphasis on educating participants about depression, raising awareness of mental illness with the goal of normalizing it and reducing stigma, and increasing healthy coping behaviors, and. 5. The intervention will be delivered by a licensed mental health clinician.
Interventions
BEHAVIORALOHDC-DC
90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
Sponsors
University of Wisconsin, Madison
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* African-American * Age 18 and older * Experiencing depression (as evidenced by a score of 5 or higher on the PHQ-9) * Own a mobile phone
Exclusion criteria
* Individuals who are currently receiving psychotherapy * Individuals who are presently experiencing suicidal ideation * Individuals who started psychotropic medication less than three months prior to the start of the OHDC will be excluded from the study * Participants scoring 25 or higher on the PHQ-9 will be screened out
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Personal Health Questionnaire Depression Scale score | Baseline to one month post-intervention (approximately 12 weeks) | Using the 8 item Personal Health Questionnaire Depression Scale (PHQ-8), participants will rate how much they have been bothered by symptoms on a scale of 0-3 with a possible range of 0 to 24. Higher scores indicate greater degree of depression. |
| Change in Generalized Anxiety Disorder 7-item (GAD-7) score | Baseline to one month post-intervention (approximately 12 weeks) | Using the GAD-7 score, participants will rate how much they have been bothered by symptoms on a scale of 0-3 with a possible range of 0 to 24. Higher scores indicate greater degree of anxiety. |
| Change in Quick Inventory of Depressive Symptomatology (QIDS) | Baseline to one month post-intervention (approximately 12 weeks) | Using the 16-item QIDS, participants will rate how much they have been bothered by symptoms on a scale of 0-3 with a possible range of 0 to 27. Higher scores indicate greater degree of depression. |
| Satisfaction with intervention | 12 weeks | Participants will rate their satisfaction with the intervention by answering a 9-item questionnaire with a scale of 1-7 (1= none of the time, 7= all of the time). Higher scores indicate greater satisfaction with the intervention. |
Countries
United States
Contacts
CONTACTShari Barlow
PRINCIPAL_INVESTIGATOREarlise Ward, PhD
University of Wisconsin, Madison
Outcome results
None listed